UTHR - United Therapeutics surges 12% on Q3 beat as Tyvaso drives sales growth

• United Therapeutics ( NASDAQ: UTHR ) stock soared ~12% on Wednesday after Q3 results surpassed analysts estimates.
• GAAP EPS rose +43.57% Y/Y to $4.91. Total revenues grew +16% Y/Y to $516M.
• "We are thrilled to report the highest quarterly revenue in our history," said United Chairperson and CEO Martine Rothblatt.
• Sales of pulmonary arterial hypertension (PAH) drug Tyvaso ( an inhalation version of treprostinil) grew 57% Y/Y to $257.7M.
• "We are extremely pleased to have achieved several commercial milestones in the third quarter, highlighted by Tyvaso becoming our first $1 billion annual run rate product," said United President and COO Michael Benkowitz.
• Sales of Remodulin (injectable version of treprostinil) fell -9% Y/Y to $114M. Orenitram (oral version of treprostinil) generated sales of $87.5M, up +3% Y/Y.
• Neuroblastoma therapy Unituxin saw a -17% Y/Y decline in sales to $46.1M. Meanwhile, sales of Adcirca fell -27% Y/Y to $10.7M.
• Q3 Research and development expenses declined to $66.1M, compared to $79.2M.

For further details see: